1,755 filings
Page 40 of 88
6-K
jw7 xqbsy2jajpfd
8 Mar 13
Teva Files 2012 Annual Report on Form 20-F
12:00am
6-K
4rma86lp5hb
6 Mar 13
Live Filing
12:00am
6-K
xuid2kp9hk357od1kv
4 Mar 13
Live Filing
12:00am
6-K
x256y
22 Feb 13
Additional QNASL® (beclomethasone dipropionate) Nasal Aerosol Data to be Presented at Annual Allergy Meeting
12:00am
6-K
w8u3nyne 0sj
14 Feb 13
Live Filing
12:00am
6-K
c6ag4yzy1k cs
11 Feb 13
Teva Pharmaceuticals Announces Appointment of Dr. Arie Belldegrun to Board of Directors
12:00am
6-K
lffm1v08k8bjdo9i61rl
7 Feb 13
Teva Reports Fourth Quarter and Full Year 2012 Results
12:00am
6-K
9zfe80
5 Feb 13
Teva Announces First Patient Enrolled In Largest Clinical Study to Date Evaluating Azilect® for Mild Cognitive Impairment In Parkinson’s Disease
12:00am
6-K
6ep7km5pnvt kmtp
31 Jan 13
Teva Announces Termination of Agreements with Curetech
12:00am
6-K
gqux6es i9
23 Jan 13
Live Filing
12:00am
6-K
ej5j23kv
20 Dec 12
Current report (foreign)
12:00am
6-K
k9twww
18 Dec 12
Teva Signs New $3.0 Billion Syndicated Revolving Credit Facility
12:00am
6-K
659uq1c
18 Dec 12
Current report (foreign)
12:00am
6-K
rvrwq5jxx3jrt8n1m
18 Dec 12
Live Filing
12:00am
6-K
c753hzq0wkh1r9gn
17 Dec 12
Teva Enters Agreement with Handok to Establish Business Venture with Significant Presence in Korean Pharmaceutical Market
12:00am
FWP
oocs2myvmb24ojffg
14 Dec 12
Free writing prospectus
12:00am
6-K
vkhdvc
14 Dec 12
Teva Announces Pricing of $2.0 Billion of Senior Notes
12:00am
424B5
uvnxfwf
14 Dec 12
Prospectus supplement for primary offering
12:00am
6-K
1vs1xx5
13 Dec 12
Teva Receives A- Rating from Fitch Ratings with a Stable Outlook
12:00am